Vector Science & Therapeutics Expands Patent Portfolio to 15 Applications Focused on Precision Delivery of Peptides and Biologics

Vector Science & Therapeutics, Corp. (TSXV: PAIN) announced on July 15, 2026, the expansion of its intellectual property portfolio to include 15 patent applications filed over approximately the past two years. The company’s IP estate focuses on precision therapeutic delivery technologies designed to overcome longstanding challenges in administering peptides and biologics to specific tissues at controlled concentrations and durations.

Headquartered in Mequon, Wisconsin, Vector’s strategy diverges from conventional approaches that target a single drug, device, or disease. Instead, the company has built a broad, interconnected portfolio of delivery technologies aimed at addressing biological, anatomical, and patient-compliance barriers that limit traditional pharmaceutical administration.

Tom Bachinski, Chief Technology Officer of Vector Science & Therapeutics, emphasized the company’s focus on the delivery challenge rather than the therapeutic molecules themselves. He stated, “We believe many promising therapeutic agents are constrained not simply by the molecule, but by the limitations of how that molecule reaches its intended target. Our intellectual property strategy is focused on the delivery problem. We are developing multiple technologies designed to move therapeutics across biological barriers, concentrate treatment at difficult-to-reach tissue and reduce unnecessary systemic exposure.”

Vector’s patent applications cover a diverse range of technologies unified by the goal of precision therapeutic delivery. These include multi-route peptide and biologic delivery systems, advanced transdermal methods, electrically assisted deep-tissue transport, interferential-hybrid iontophoresis, localized catheter delivery, lyophilized pharmaceutical formulations with point-of-care reconstitution, electrostatic spray administration, magnetic field-assisted delivery, microneedle and intratumoral systems, nanoparticle-enabled transport, and sensor-guided treatment platforms.

Several patent filings integrate multiple engineering and pharmaceutical disciplines within single therapeutic systems. These systems combine drug formulation, delivery hardware, electrical or electromagnetic energy, tissue sensing, feedback control, and targeted release mechanisms.

- Advanced Therapeutic and Peptide Delivery: Multi-route technologies addressing the challenges of delivering peptides, biologics, and other complex agents via non-gastrointestinal and non-traditional pathways such as transdermal, iontophoretic, and lyophilized reconstitution systems specifically engineered for peptide formulations.

- Deep-Tissue Transdermal Delivery: Interferential-hybrid iontophoresis systems that combine tissue pre-conditioning with electrically driven therapeutic transport and retention phases.

- Opioid-Sparing and Localized Pain Management: Lyophilized multimodal analgesic compositions, integrated reconstitution kits, and localized administration technologies designed to support targeted pain relief strategies.

- Precision Pancreatic Oncology: Endoscopic ultrasound (EUS)-guided multimodal therapies, microneedle-tipped intratumoral delivery, conductivity and impedance-guided treatment, transarterial pancreatic delivery, and anchored catheter systems for sustained locoregional administration.

- Regenerative Medicine and Tissue Repair: Non-invasive delivery systems, including peptide-based regenerative technologies targeting musculoskeletal and peripheral nerve tissues.

- Advanced Smart Wound Care: Integrated wound-healing platforms combining responsive therapeutic release, oxygenation, multi-wavelength phototherapy, and real-time wound monitoring within automated treatment systems.

Peptide and biologic delivery is a recurring theme throughout Vector’s portfolio, with multiple applications specifically addressing the challenge of transporting peptide therapeutics across biological barriers without relying solely on oral or systemic administration. Technologies include multi-route, non-gastrointestinal delivery architectures; interferential-hybrid iontophoresis for non-invasive regenerative peptide delivery; and lyophilized, point-of-care reconstitution platforms that stabilize peptide formulations at the time of use.

Peptides pose unique delivery challenges due to their instability in the gastrointestinal tract, short circulating half-lives, and frequent need for injection or specialized formulations to maintain efficacy. Vector’s intellectual property aims to mitigate these issues by enabling non-invasive and minimally invasive delivery routes, enhancing formulation stability, and providing localized administration systems that reduce dependence on injections. These platforms have potential applications across metabolic, regenerative, and oncology indications, complementing peptide therapeutics developed by other entities.

Vector describes its technology strategy as addressing the “last mile of therapeutics”—the physical and biological distance between a therapeutic agent and the target tissue. Conventional systemic administration often exposes the entire body to a drug while delivering only a fraction to the intended site. Passive transdermal delivery faces the skin’s natural barrier, injectable therapies may pose compliance challenges, and solid tumors present stromal and vascular barriers that impede penetration.

The company’s intellectual property portfolio is designed to overcome these delivery barriers through combinations of localized access, physical energy application, formulation science, targeted transport, and real-time treatment control. This comprehensive approach positions Vector Science & Therapeutics at the forefront of precision therapeutic delivery innovation.